Fibroblast Cell Signaling in Utero Nicotine-Induced Lung Injury

子宫内尼古丁引起的肺损伤中的成纤维细胞信号传导

基本信息

项目摘要

DESCRIPTION (provided by applicant): Maternal smoking during pregnancy causes a broad range of effects on the developing lung of the fetus that greatly impairs its long-term function and capacity. The molecular mechanisms underlying these effects are not known. Since both normal lung development and injury/repair utilize common alveolar epithelial-mesenchymal signaling pathways to maintain homeostasis, we propose that in utero nicotine exposure disrupts the critical homeostatic epithelial-mesenchymal paracrine signaling pathways, resulting in the transdifferentiation of alveolar intersitial fibroblasts (AIFs) to myofibroblasts (MYFs). This AIF-to-MYF transdifferentiation is characterized by down regulation of the Peroxisome Proliferator Activated Receptor gamma (PPAR() signaling pathway and up regulation of the Wingless/Int (Wnt) signaling pathway. Although the effects of in utero nicotine exposure on PPAR( signaling have recently been described, there is no information on its effect on the Wnt signaling in the developing lung. We hypothesize that in utero nicotine exposure up-regulates AIF Wnt signaling and that by specific molecular targeting to down regulate the Wnt signaling and/or up regulate the PPAR( signaling, in utero nicotine-induced lung injury can be prevented or even reversed. Using well established in vitro and in vivo models of in utero nicotine-induced lung injury, through real-time RT- PCR, Western analysis, immunohistochemistry, laser capture microdissection, metabolomics, antisense and over expression studies, and in vivo pulmonary function tests, we will determine (1) how in utero nicotine exposure alters lung development, resulting in altered structure and function, and (2) if PPAR( agonists and/or Wnt antagonists, either alone or in combination, can prevent and/or reverse perinatal nicotine exposure-induced alterations in PPAR( and Wnt signaling in lung mesenchyme, and hence lung structure and function. Since the paradigm and models used by us are based on a universal developmental model for the formation, establishment, and homeostasis of the alveolar acinus, the information generated will not be limited only to in utero nicotine-induced injury but is likely to have a much larger applicability to lung development and injury/repair in general. Therefore, by utilizing functional genomics, the studies proposed herein are likely to translate into novel and innovative molecular preventive and therapeutic approaches for all chronic lung diseases in general. PROJECT NARRATIVE: Maternal smoking during pregnancy poses significant risks not only during gestation and immediate newborn period, but may also results in life long medical complications including devastating respiratory problems. The mechanisms underlying the harmful effects of maternal smoking on the lung are complex and incompletely understood. Using novel and innovative concepts, and the state-of-the-art technology, the proposed studies will unravel mechanisms that underlie not only the in utero smoke exposure-induced lung injury, but also almost all other forms of chronic lung diseases.
描述(由申请人提供):母亲在怀孕期间吸烟对胎儿发育中的肺造成广泛影响,极大地损害其长期功能和能力。这些效应背后的分子机制尚不清楚。由于正常的肺发育和损伤/修复都利用共同的肺泡上皮-间充质信号通路来维持稳态,我们提出,在子宫内尼古丁暴露破坏了关键的稳态上皮-间充质旁分泌信号通路,导致肺泡间质成纤维细胞(AIF)转分化为肌成纤维细胞(MYF)。这种AIF到MYF的转分化的特征在于过氧化物酶体激活受体γ(PPAR 0)信号通路的下调和无翅/Int(Wnt)信号通路的上调。尽管最近描述了子宫内尼古丁暴露对PPAR α信号传导的影响,但没有关于其对发育中的肺中Wnt信号传导的影响的信息。我们假设子宫内尼古丁暴露上调AIF Wnt信号传导,并且通过特异性分子靶向下调Wnt信号传导和/或上调PPAR(信号传导,子宫内尼古丁诱导的肺损伤可以被预防甚至逆转。使用已建立的子宫内尼古丁诱导的肺损伤的体外和体内模型,通过实时RT-PCR、Western分析、免疫组织化学、激光捕获显微切割、代谢组学、反义和过表达研究以及体内肺功能测试,我们将确定(1)子宫内尼古丁暴露如何改变肺发育,导致结构和功能改变,和(2)单独或组合的PPAR 0激动剂和/或Wnt拮抗剂是否可以预防和/或逆转围产期尼古丁阻断诱导的肺间质中PPAR 0和Wnt信号传导的改变,从而预防和/或逆转肺结构和功能的改变。由于我们使用的范例和模型是基于肺泡腺泡的形成、建立和稳态的通用发育模型,所产生的信息将不仅限于子宫内尼古丁诱导的损伤,而且可能对肺发育和损伤/修复具有更大的适用性。因此,通过利用功能基因组学,本文提出的研究可能转化为一般所有慢性肺部疾病的新颖和创新的分子预防和治疗方法。项目叙述:母亲在怀孕期间吸烟不仅在怀孕期间和新生儿期造成重大风险,而且还可能导致终身医疗并发症,包括毁灭性的呼吸系统问题。母亲吸烟对肺部有害影响的潜在机制是复杂的,尚未完全了解。利用新颖和创新的概念以及最先进的技术,拟议的研究将揭示不仅是子宫内烟雾诱导的肺损伤,而且几乎所有其他形式的慢性肺部疾病的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VIRENDER K REHAN其他文献

VIRENDER K REHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VIRENDER K REHAN', 18)}}的其他基金

Advancing Small Molecule Read Through Compounds to Prevent and/or Treat Heritable Pulmonary Artery Hypertension
推进小分子化合物读取以预防和/或治疗遗传性肺动脉高血压
  • 批准号:
    10011012
  • 财政年份:
    2020
  • 资助金额:
    $ 28.38万
  • 项目类别:
Developmental Nicotine Exposure & Transgenerationally Altered Lung Phenotype
发育期尼古丁暴露
  • 批准号:
    9027005
  • 财政年份:
    2016
  • 资助金额:
    $ 28.38万
  • 项目类别:
In Utero Nicotine Exposure & Transgenerational Transmission of Asthma
子宫内尼古丁暴露
  • 批准号:
    8502717
  • 财政年份:
    2012
  • 资助金额:
    $ 28.38万
  • 项目类别:
In Utero Nicotine Exposure & Transgenerational Transmission of Asthma
子宫内尼古丁暴露
  • 批准号:
    8398879
  • 财政年份:
    2012
  • 资助金额:
    $ 28.38万
  • 项目类别:
Molecular Basis of Childhood Asthma Following Perinatal Vitamin D Deficiency
围产期维生素 D 缺乏后儿童哮喘的分子基础
  • 批准号:
    8176951
  • 财政年份:
    2011
  • 资助金额:
    $ 28.38万
  • 项目类别:
Molecular Basis of Childhood Asthma Following Perinatal Vitamin D Deficiency
围产期维生素 D 缺乏后儿童哮喘的分子基础
  • 批准号:
    8298583
  • 财政年份:
    2011
  • 资助金额:
    $ 28.38万
  • 项目类别:
CARDIAC TROPONIN- T: A SPECIFIC BIOCHEMICAL MARKER OF MYOCARDIAL DYSFUNCTION, MO
心肌肌钙蛋白-T:心肌功能障碍的特定生化标志物,MO
  • 批准号:
    8174521
  • 财政年份:
    2009
  • 资助金额:
    $ 28.38万
  • 项目类别:
A Molecular Approach to Prevent Pulmonary Dysfunction in the Intrauterine Growth
预防宫内生长过程中肺功能障碍的分子方法
  • 批准号:
    7739532
  • 财政年份:
    2009
  • 资助金额:
    $ 28.38万
  • 项目类别:
A Molecular Approach to Prevent Pulmonary Dysfunction in the Intrauterine Growth
预防宫内生长过程中肺功能障碍的分子方法
  • 批准号:
    7936249
  • 财政年份:
    2009
  • 资助金额:
    $ 28.38万
  • 项目类别:
Fibroblast Cell Signaling in Utero Nicotine-Induced Lung Injury
子宫内尼古丁引起的肺损伤中的成纤维细胞信号传导
  • 批准号:
    8309208
  • 财政年份:
    2008
  • 资助金额:
    $ 28.38万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 28.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了